Overview

Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis

Status:
Recruiting
Trial end date:
2027-06-14
Target enrollment:
Participant gender:
Summary
The study will determine the optimal dosing regimen of LNA043 in patients with knee osteoarthritis (OA).
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals